GSK PLC closed 22.73% below its 52-week high of £18.24, which the company reached on May 16th.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...

NET PROFIT FORECAST: Net profit is expected to rise to 1.67 billion pounds from 1.05 billion pounds, according to a consensus provided by the company. London-listed shares in GSK are up 4.1% since the ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and prescription ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...